


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:


1. - 37. (Canceled).

38. (Currently Amended) A method of treating seborrheic dermatitis in a human or animal patient in need of treatment for ~~seborrheic dermatitis~~ thereof comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition comprising:

(A) an a sole active component consisting ~~essentially~~ of at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) $-CR_2-$, where R is H or (C_1-C_4) -alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;

and


Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy; and

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and


wherein the composition has a pH ranging from about 4.5 to about 6.5.

39. (Currently Amended) A method of treating seborrheic dermatitis in a human or animal patient in need of treatment for seborrheic dermatitis thereof comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:

(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R¹, R², and R³, which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) -CR₂-, where R is H or (C₁-C₄)-alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain, which optionally further comprises one or more of the following:

- (i) a carbon-carbon double bond, and
- (ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether; and

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

40. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal patient in need of treatment for seborrheic dermatitis~~ thereof as claimed in claim 38 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has a cyclohexyl radical in the R⁴ position.

41. (Currently Amended) A method of treating seborrheic dermatitis in a human
~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in
claim 38 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has an
octyl radical of the formula $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{CH}_3)_3$ in the R^4 position.

42. (Currently Amended) A method of treating seborrheic dermatitis in a human
~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in
claim 38 in which the ~~pharmaceutical composition comprises~~ sole active component
consists of 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxyethyl)-2(1H)pyridone,
1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-
trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the
foregoing, or a mixture of any of the foregoing.


43. - 47. (Canceled).

48. (Currently Amended) A method of treating seborrheic dermatitis in a human
~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in
claim 38 in which the ~~pharmaceutical~~ composition further comprises at least one
additional surfactant chosen from anionic, cationic, nonionic, and amphoteric
surfactants.


49. - 52. (Canceled).

53. (Currently Amended) A method of treating seborrheic dermatitis in a human
~~or animal patient in need of treatment for seborrheic dermatitis thereof~~ comprising
administering to the patient an amount effective for the treatment of seborrheic
dermatitis of a composition comprising:

(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-
hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X is S or O;

Y is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) -CR₂-, where R is H or (C₁-C₄)-alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;

and

Ar is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy;

(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and

(C) at least one keratolytic agent; and

wherein the composition has a pH ranging from about 4.5 to about 6.5.

54. (Previously Presented) The method of claim 53, wherein the keratolytic agent is one or more of the agents selected from the group consisting of sulfur, salicylic acid, and enzymes.

55. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 53 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has a cyclohexyl radical in the R⁴ position.

56. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 53 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the R⁴ position.


57. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 53 in which the ~~pharmaceutical~~ composition comprises 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxy)methyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-

2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any of the foregoing.


58. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 53 in which the pharmaceutical composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

59. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 39, in which the composition further comprises ~~comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:~~

~~(A) at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt;~~



where R¹, R², and R³, which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:



where:

X— is S or O;

Y— is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z— is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) CR₂, where R is H or (C₁-C₄) alkyl, or

~~(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,
which optionally further comprises one or more of the following:~~

~~(i) a carbon-carbon double bond, and~~

~~(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a
mixture thereof are present, each O or S atom is separated by at least 2
carbon atoms; and,~~

~~in any of the foregoing linking radicals, any remaining free valences of the carbon
atoms of said linking radical are saturated by H, (C₁-C₄) alkyl, or a mixture
thereof;~~

~~and~~

~~Ar— is an aromatic ring system having two rings, the aromatic ring system being
unsubstituted or substituted by one, two, or three radicals, which are identical or
different, and are chosen from halogen, methoxy, (C₁-C₄) alkyl, trifluoromethyl,
and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl,
diphenylalkane, or diphenyl ether;~~

~~B) — at least one surfactant chosen from anionic surfactants, cationic surfactants,
nonionic surfactants, and amphoteric surfactants; and~~

~~(G) at least one keratolytic agent.~~

60. (Previously Presented) The method of claim 59, wherein the keratolytic agent is one or more of the agents selected from the group consisting of sulfur, salicylic acid, and enzymes.

61. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of ~~treatment for seborrheic dermatitis~~ thereof as claimed in claim 59 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has a cyclohexyl radical in the R⁴ position.


62. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of ~~treatment for seborrheic dermatitis~~ thereof as claimed in claim 59 in which the at least one 1-hydroxy-2-pyridone of formula I ~~comprises~~ has an octyl radical of the formula -CH₂-CH(CH₃)-CH₂-C(CH₃)₃ in the R⁴ position.

63. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of ~~treatment for seborrheic dermatitis~~ thereof as claimed in claim 59 in which the ~~pharmaceutical~~ composition comprises 1-hydroxy-4-methyl-6-(4-(4-chlorophenoxy)phenoxy)methyl)-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone, or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone, or a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any of the foregoing.


64. (Currently Amended) A method of treating seborrheic dermatitis in a human ~~or animal~~ patient in need of ~~treatment for seborrheic dermatitis~~ thereof as claimed in claim 59 in which the ~~pharmaceutical~~ composition further comprises at least one additional surfactant chosen from anionic, cationic, nonionic, and amphoteric surfactants.

65. (Currently Amended) A method of treating seborrheic dermatitis in a human
or animal patient in need of treatment for seborrheic dermatitis thereof as claimed in
claim 38, in which the composition further comprises
comprising administering to the patient an amount effective for the treatment of
seborrheic dermatitis of a composition comprising:

(A) an active component consisting essentially of at least one 1-hydroxy-2-pyridone
of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as
a pharmaceutically acceptable salt:



where R^1 , R^2 , and R^3 , which are identical or different, are H or alkyl having 1 to 4 carbon
atoms, and R^4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a
radical of formula II:



where:

~~X — is S or O;~~

~~Y — is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;~~

~~Z — is a single bond, or~~

~~a linking radical comprising~~

~~(1) O, or~~

~~(2) S, or~~

~~(3) CR₂, where R is H or (C₁-C₄)-alkyl, or~~

~~(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,~~

~~which optionally further comprises one or more of the following:~~

~~(i) a carbon-carbon double bond, and~~

~~(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,~~

~~in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄)-alkyl, or a mixture thereof;~~

~~and~~

~~Ar — is an aromatic ring system having one or two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄)-alkyl, trifluoromethyl, and trifluoromethoxy;~~

(B) ~~at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants;~~


(G) ~~lactic acid ; and~~

~~wherein the composition has a pH ranging from about 4.5 to about 6.5.~~


66. (Currently Amended) A method of treating seborrheic dermatitis in a human or animal patient in need of treatment for seborrheic dermatitis thereof as claimed in claim 39, in which the composition further comprises

~~comprising administering to the patient an amount effective for the treatment of seborrheic dermatitis of a composition which comprises:~~

(A) ~~at least one 1-hydroxy-2-pyridone of formula I, wherein the at least one 1-hydroxy-2-pyridone is present in free form or as a pharmaceutically acceptable salt:~~



~~where R¹, R², and R³, which are identical or different, are H or alkyl having 1 to 4 carbon atoms, and R⁴ is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of formula II:~~



where:

X— is S or O;

Y— is H, or 1 or 2 identical halogen atoms, or a mixture of 2 different halogen atoms;

Z— is a single bond, or

a linking radical comprising

(1) O, or

(2) S, or

(3) CR₂, where R is H or (C₁-C₄) alkyl, or

(4) from 2 to 10 carbon atoms linked in the form of a straight or branched chain,

which optionally further comprises one or more of the following:

(i) a carbon-carbon double bond, and

(ii) O, S, or a mixture thereof, wherein if 2 or more O or S atoms or a mixture thereof are present, each O or S atom is separated by at least 2 carbon atoms; and,

in any of the foregoing linking radicals, any remaining free valences of the carbon atoms of said linking radical are saturated by H, (C₁-C₄) alkyl, or a mixture thereof;

and

~~Ar is an aromatic ring system having two rings, the aromatic ring system being unsubstituted or substituted by one, two, or three radicals, which are identical or different, and are chosen from halogen, methoxy, (C₁-C₄) alkyl, trifluoromethyl, and trifluoromethoxy, and wherein Ar is a bicyclic system derived from biphenyl, diphenylalkane, or diphenyl ether;~~

~~(B) at least one surfactant chosen from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants; and~~

~~(C) lactic acid.~~

67. (New) A method of treating seborrheic dermatitis in a human patient in need thereof as claimed in claim 39, in which the composition is free of a halogenated antibacterial agent.